A Bridging Study of the SYN023 on Healthy Adult Subjects
A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies (ADA) of a Single Intramuscular Doses of SYN023 in Healthy Adult Subjects
Sponsor: Synermore Biologics (Suzhou) Co., Ltd.
This PHASE1/PHASE2 trial investigates Communicable Disease Transmission and Immunisation Reaction and is currently completed. Synermore Biologics (Suzhou) Co., Ltd. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Synermore Biologics (Suzhou) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .